Adagene

Adagene Current Ratio

The Current Ratio of Adagene (ADAG) as of Oct 17, 2026 is 3.74. In the previous year, Current Ratio was 2.33 — a change of 60.43% (higher).

Current Ratio

3.74

YoY

60.43%

Last updated:

Current Ratio of Adagene is 2025 3.74 . Current Ratio of Adagene was 2024 2.33 . It decreases by 60.43% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adagene Stock analysis

What does Adagene do? Adagene Inc., based in Suzhou, China, is a clinical-stage biotechnology company focused on developing monoclonal antibody drugs for cancer treatment. The company operates in the Health Care sector, with its lead candidates ADG126 and ADG116 in phase 1b/2 trials for various cancers, alongside other pipeline products in clinical and preclinical stages. Listed on 9 February 2021, Adagene employs 128 people and is dedicated to advancing innovative therapies for solid tumors and hematologic malignancies. Adagene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adagene stock

Current Ratio of Adagene is 3.74 in 2025.

Current Ratio of Adagene changed from 2.33 to 3.74, representing a 60.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio Adagene since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Adagene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Adagene

All Key Metrics — Adagene